Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01140178
Other study ID # I 170910
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date June 8, 2010
Est. completion date October 1, 2018

Study information

Verified date October 2018
Source Roswell Park Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Recent literature suggests that certain patients with squamous cell cancers of the head and neck region may benefit from photodynamic therapy whether or not they may have received prior therapy, e.g. radiation therapy


Description:

We propose to initiate a Phase 1 a clinical trial using HPPH and 665 nm light in patients with cancer of the oral cavity and/or oropharynx, including lesions of moderate to severe dysplasia, squamous carcinoma in situ and T1 squamous cells carcinoma. The study will employ a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively. The primary goal is the determination of the maximally tolerated PDT dose. Preliminary evidence for PDT efficacy wil also be obtained.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date October 1, 2018
Est. primary completion date January 29, 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with moderate to severe dysplasia and/or squamous carcinoma-in-situ of the oral cavity and/or oropharynx.

- Patients with T1 squamous cell carcinoma of the oral cavity and/or oropharynx.

- Patient may have primary and/or recurrent lesions to be treated.

- Diagnosis must confirmed by biopsy.

- Prior therapy of any type is allowed.

- Male or female patients at least 18 years old. Female patients must not be pregnant and must be practicing a medically acceptable form of birth control, be sterile or post-menopausal. Male patients should be using a medically acceptable form of birth control or be sterile.

- Patients must have an ECOG score of 0-2 (Appendix A 1 ).

- Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion Criteria:

- Patients with T2 or greater squamous cell carcinoma.

- True tongue base lesions (as determined by the treating physician).

- Patients with severe trismus that prevents adequate access to the lesion for treatment light delivery (as determined by the treating physician).

- Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds.

- Patients with impaired hepatic (alkaline phosphatase (hepatic) or SGOT;:3 times the upper normal limits).

- Patients with minimal impairment of renal function (total serum bilirubin;: 2 mg/dl, serum creatinine;: 2 mg/dl)

- Unwilling or unable to follow protocol requirements.

- Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug and or light treatment.

- Patients on concurrent chemotherapy or radiation therapy or less than 4 weeks after the last dose of chemotherapy or radiation therapy.

Inclusion of Women and Minorities:

- Both men and women and members of all races and ethnic groups are eligible for this study.

Study Design


Intervention

Drug:
HPPH
Given IV

Locations

Country Name City State
United States Roswell Park Cancer Institute Buffalo New York

Sponsors (2)

Lead Sponsor Collaborator
Roswell Park Cancer Institute National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity To determine the maximally tolerated dose in the oral cavity and/or oropharynx of photodynamic therapy (PDT) using HPPH (2-1 (hexyloxyethyl)-2- devinylpyropheophorbide-a) and 665 nm light. 6 weeks
Secondary Tumor response 3 months
Secondary Response of dysplasia, CiS and selected patients with T1 squamous cell carcinoma of the oral cavity and/or oropharynx using photodynamic therapy (PDT) with HPPH (2-1 (hexyloxyethyl)-2-devinylpyropheophorbide-a) and 665 nm light. 3 months
Secondary Amount of HPPH in the blood prior to light treatment. 3 months
Secondary Biomarkers, i.e. STAT3 crosslinks and/or activation status of pro-survival signaling molecules before and after PDT treatment. 3 months
Secondary To determine non-invasively HPPH fluorescence and blood flow in To determine non-invasively HPPH fluorescence and blood flow in tumor and surrounding normal tissue before and after PDT 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05809999 - IBD Neoplasia Surveillance RCT N/A
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Completed NCT05161013 - A Proof-of-Concept Study Evaluating LINFU™ N/A
Terminated NCT01013831 - Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung Phase 1
Completed NCT04072913 - Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix N/A
Completed NCT04067778 - IBD Neoplasia Surveillance Pilot RCT N/A
Recruiting NCT06281392 - Artificial Intelligence and Dysplasia Detection in Inflammatory Bowel Disease (EIIDISIA Study) N/A
Completed NCT05171634 - Artificial Intelligence and Dysplasia Detection in Ulcerative Colitis (CUDISIA Study) N/A
Recruiting NCT06430372 - Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract Phase 1
Active, not recruiting NCT02790853 - Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders Early Phase 1
Recruiting NCT04867590 - A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus N/A
Completed NCT02075905 - Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management N/A
Terminated NCT02481687 - The Value of I-Scan and Confocal Laser Endomicroscopy for the Assessment of Chronic Inflammatory Bowel Disease N/A
Completed NCT01799200 - Hip Pathomorphology in Collegiate Athletes and Controls N/A
Recruiting NCT04054713 - Acetic Acid for the Detection of Esophageal Neoplasms N/A
Completed NCT03268993 - Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer N/A
Active, not recruiting NCT01816438 - A French Non Interventional Multicentric Cohort Study in Patients With Colorectal Dysplasia
Terminated NCT00358111 - Study of LUMA Cervical Imaging System as Adjunct to Colposcopy Phase 4
Active, not recruiting NCT01688908 - Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC) N/A
Completed NCT02100189 - Esophageal Cytology With FISH in Detecting Esophageal Cancer N/A